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Abstract 
Polyphenols have been extensively studied for their antioxidant and anti-inflammatory properties. 
Recently, their antiglycative actions by oxidative stress modulation have been linked to 
prevention of diabetes and associated complications. This paper assesses the evidence for 
polyphenol interventions on glycohaemoglobin (HbA1c) in non-diabetic, pre-diabetic and type 2 
diabetes mellitus (T2DM) subjects. A systematic review of polyphenols clinical trials on HbA1c 
in humans was performed according to the Preferred Reporting Items for Systematic Review and 
Meta-Analysis. Thirty-six controlled randomized trials with HbA1c values were included. 
Polyphenols (extracts, supplements, foods), were supplemented (28 mg to 1.5g) for 0.7 to 12 
months. Combining all subjects (n=1954, mean baseline HbA1c=7.03%, 53 mmol/mol), 
polyphenol supplementation significantly (p<0.001) lowered HbA1c% by -0.53±0.12 units (-
5.79±0.13 mmol/mol). This reduction was significant (p<0.001) in T2DM subjects, specifically 
(n=1426, mean baseline HbA1c=7.44%, 58 mmol/mol), with HbA1c% lowered by -0.21±0.04 
units (-2.29±0.4 mmol/mol). Polyphenol supplementation had no significant effect (p>0.21) in 
the non-diabetic (n=258, mean baseline HbA1c=5.47%, 36 mmol/mol) and the pre-diabetic 
subjects (n=270, mean baseline HbA1c=6.06%, 43 mmol/mol) strata: -0.39±0.27 HbA1c% units 
(-4.3±0.3 mmol/mol), and -0.38±0.31 units (-4.2±0.31 mmol/mol), respectively. In conclusion, 
polyphenols can successfully reduce HbA1c in T2DM, without any intervention at glycaemia, 
and could contribute to the prevention of diabetes complications.  
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Introduction 
Hyperglycaemia is clearly recognized as the primary factor in the onset and progression of 
diabetes. Both acute and chronic hyperglycemia enhance the formation of early, intermediate and 
advanced glycation endproducts (AGEs), leading to a series of pathogenic complications (Jakuš 
et al., 2004). AGEs are complex, heterogeneous, and chemically stable which progressively 
accumulate on the tissue and organs developing chronic complications of diabetes, such as 
retinopathy, nephropathy, neuropathy, micro and macrovasculopathies (Jakuš et al., 2004). 
Glycohaemoglobin (HbA1c) is an early glycation product and a marker of chronic glycaemia 
from the preceding 2 to 3 months (Singh et al., 2001; Diagnosis and classification of diabetes 
mellitus  2012). HbA1c correlates with both micro and macrovascular complications and is 
considered as the standard biomarker for glycaemic management (Diagnosis and classification of 
diabetes mellitus  2012). 
Conceding that glycated products are involved in the pathogenesis of diabetes, anti-glycation 
treatments may assist in the prevention of diabetes and their complications. Nutritional 
interventions, especially those involving plant foods and beverages or specific phytochemicals, 
have attracted attention for the management diabetes and its complications. Polyphenols are one 
of these major classes of phytochemicals. Ubiquitous in plant foods, they have a wide range of 
chemical structures usually comprising at least one aromatic ring with hydroxyl groups (Xie et 
al., 2013; Crozier et al., 2009). This wide structural variation, including their substituents, has 
given to polyphenols their different levels of anti-AGEs and anti-diabetic activities demonstrated 
in vivo and in vitro studies (Xie et al., 2013; Klein et al., 2011b). While the original paradigm 
indicated the antiglycative effect of polyphenols was due to their free radical scavenging 
potential, new evidence of scavenging-independent protection has emerged (Vlassopoulos et al., 
2013; Sadowska-Bartosz et al., 2014; Mandeville et al., 2009). 
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HbA1c has a higher positive predictive value to identify people at risk of diabetes and 
cardiovascular complications. Hence, concentrations in the range of 5.5 to 6% are appropriate to 
initiate preventive interventions (Diagnosis and classification of diabetes mellitus  2012). 
Nutrition is a potential tool in regulating glucose metabolism, and it has been reported that 
dietary polyphenol might be protective (Hanhineva et al., 2010). There are several studies and 
reviews addressing the beneficial effects of polyphenols on humans and animal as well as in vitro 
models on the glycaemic control and cardiovascular risk factors in patients with diabetes 
(Rosenow et al., 2012; Overman et al., 2011; Chuang et al., 2011; Biesalski 2007). However, the 
results of human clinical trials investigating the effects of polyphenols on glycation have 
presented inconsistent results, with some of them presenting short intervention periods that 
cannot reflect any change during this time frame. Therefore, the present systematic review aimed 
to evaluate the current published randomized controlled trials related to polyphenol 
supplementation on HbA1c concentrations in non-diabetic, pre-diabetic and type 2 diabetes 
mellitus (T2DM) subjects.  
 
Methods 
The present systematic review and meta-analysis was conducted according to the Preferred 
Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guideline (Moher et al., 
2009). A literature research was carried out on PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), 
and ISI Web of Knowledge for randomized clinical trials that examined the effects of 
polyphenols on glycohaemoglobin conducted in human subjects. The database search included all 
studies published before February 2014. The following search terms were used to identify 
relevant studies: phenol, polyphenol, phytoestrogen, resveratrol, ellagitan, elligitan, catechin, 
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flavan, flavon, fruit, vegetable, spice, tea, cocoa, coffee or juice, which were paired with 
treatment, intervention, or supplementation. The terms glycation, glycated, haemoglobin, HbA1c 
or glycohaemoglobin were used as well. The wild-card term “*” was used to improve the 
sensitivity of the search by increasing the number of matches. The references of all relevant trials 
and reviews were hand-searched for additional studies.  
Study Selection 
Studies were chosen for analysis if they met the following criteria: (1) the systematic review was 
restricted to the reports of clinical trials conducted in non-diabetic, pre-diabetic and diabetic 
subjects without any diabetic complications; (2) the articles were published in English or the 
abstracts were available in English; (3) studies were controlled parallel or cross-over randomized 
trials supplemented with polyphenols in form of supplements (oral capsules, extracts, powders), 
or specific foods and beverages; (4) the baseline and endpoint of glycohaemoglobin values or 
their differences were available with SDs, SEs, or 95% confidence intervals (CIs); and (5) a 
concurrent control group was included for the polyphenol group where the only difference 
between them was the polyphenol supplementation. Studies were excluded when polyphenols 
were given as part of multicomponent treatment. When data were insufficient, the authors were 
contacted to obtain additional study details and confirm their eligibility.  
Data Extraction and Quality Assessment 
Search, data collection, and quality assessment were carried out independently by two reviewers, 
divided into non-diabetics (including pre-diabetic trials), and T2DM trials according to the 
inclusion criteria. Title and abstracts were inspected for potential inclusion and duplicates were 
removed. Full-text articles were attained for further screening of suitability, reference lists were 
also screened for inclusion. Data on treatment, study design, subjects’ characteristics, number of 
participants, year of publication, period of intervention, and effect of intervention on glycation 
6 
 
[Escriba texto] 
 
were extracted from all the acquired articles. All the authors reviewed the collected data before 
conducting the statistical analyses. For any discrepancy between them a discussion was held until 
a consensus was reached. If HbA1c values were reported multiple times in different stage during 
the trial, only final values were included in the meta-analysis. Additionally, all HbA1c 
concentrations were dually reported as % and mmol/mol. HbA1c concentrations were converted 
between NGSP (National Glycohemoglogin Standardization Program) values in percentage to 
IFCC (International Federation of Clinical Chemistry) values in mmol/mol using the equation 
NGSP = [0.09148 * IFCC] + 2.152). 
The quality of the included articles was estimated using the following criteria: (1) randomization, 
(2) minimal risk of bias during patient allocation, (3) blinding, (4) report of the number of 
withdraws and explanation for withdrawal, (5) comparability of control and polyphenol 
supplemented group at baseline, (6) intention-to-treat analysis, (7) a clearly describe intervention 
procedure (Higgins 2008). Authors (SP, AV) scored the articles, attributing one point per each 
criteria addressed in the study design, toward a possible score of 0 (lowest quality) to 7 (highest 
quality). Studies receiving a score ≥5 were deemed to be of high quality, whereas those with a 
score <5 were considered of low quality. 
Statistical Analysis 
The meta-analysis was performed using NCSS 2007 version: 07.1.20, 2010 (Hintze, J. 2009, 
NCSS, LLC. Kaysville, Utah) and Comprehensive Meta-analysis (Biostat Inc, 2009, Englewood 
USA). Studies were stratified according to health status as non-diabetic, pre-diabetic and T2DM 
for analysis. Diabetes mellitus and other categories classification was established according to the 
report of WHO consultation; Diagnosis and Classification of Diabetes Mellitus and Use of 
glycated haemoglobin in diagnosis of diabetes mellitus: abbreviated report of a WHO 
consultation (Consultation 1999; Organization 2011). HbA1c was presented as % at baseline and 
7 
 
[Escriba texto] 
 
at the end of the polyphenol supplementation. When not directly available, SDs were calculated 
from SEs or 95% CIs. To avoid double-counting of subjects, and unit-of-analysis error, the 
control group, in trials with more than one treatment arm, was divided according to the number of 
subgroups within the trial. Meta-analysis was performed using a correlation coefficient (R)=0.5 
between groups to allow the calculation of variance used to weight each study and estimate the 
variance of the combined effects, as described by Follmann (Follmann et al., 1992). Difference in 
mean ± SE were calculated for net difference in HbA1c%, presented along 95% CIs, with 
equivalence for the net change in mmol/mol ± SE. The effect of heterogeneity of treatment 
between studies was tested using the Cochran’s Q test (study-by-treatment interaction, P <0.1). 
Additionally, the I
2
 statistic was also examined, I
2
 > 50% was considered as an indicator of 
heterogeneity among trials. A random-effects model was used if a significant heterogeneity was 
presented. The results of meta-analysis were explained by forest plot of the mean difference (95% 
CI). Moreover, to evaluate the influence of each study on the effect size, a sensitivity analysis 
was accomplished using the one-study remove approach. To examine potential publication bias, 
Egger regression test and funnel plots were assessed. Following the meta-analysis, the pooled 
effect size (ES) was calculated using the equation ES= mean difference/ (√N x SE of the 
difference). 
 
Results 
Study selection 
The flow diagram of the identification process for eligible studies is shown in Figure 1. Initially, 
926 potential eligible studies were identified through PubMed and Web of Knowledge. After 
exclusion of non-clinical trials, publications not written in English or irrelevant to the purpose of 
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the review, 83 articles were assessed for full-text eligibility. After full-text review, 36 
randomized control trials (RCT) were excluded due to lack of HbA1c measurement, HbA1c 
measurement not reported, only HbA1c baseline concentrations reported, HbA1c measurements 
not published despite measurement, authors not replying to emails, or polyphenols provided as 
part of a multicomponent treatment. Finally, 36 studies were selected for inclusion in the 
systematic review. 
Study characteristics 
The identified trials were divided as non-diabetic, pre-diabetic and T2DM. The characteristics of 
the trials are shown in Table 1, 2 and 3 for non-diabetic, pre-diabetic, and T2DM, respectably. A 
total of 1954 subjects were included in our study; 528 non-diabetics and 1426 T2DM. Some trials 
included non-diabetic and T2DM subjects and these studies were divided for the analysis. HbA1c 
concentrations for each stratum are presented in Table 4 in % and mmol/mol. 
A variety of polyphenols were given, more often as extracts or powders, obtained from 
polyphenol-rich foods and offered as capsules for ingestion (n=27 studies). The principal sources 
of polyphenols were green tea, juice, cinnamon, and chocolate bar. The total amount of 
polyphenol supplement given ranged from 28 mg to 1.5 g per day. The intervention studies lasted 
from under one month to one year, with three months the most common duration. Most studies 
(20 out of 36) were double blind trials. The trials varied in size from 18 to 95 subjects for non-
diabetic, 19 to 123 subjects for pre-diabetic, and from 12 to 114 subjects for T2DM interventions. 
Study settings were diverse, with 15 studies from Asia, 9 from the US, 8 from Europe, and 4 
from elsewhere (Australia, Brazil, Canada and Mauritius). Subjects in the T2DM trial group were 
conventionally medicated, most of them with metformin while non-diabetic subject were not 
medicated.  
9 
 
[Escriba texto] 
 
Data quality  
Study quality was evaluated for all trials and the results are presented in Table 1, 2 and 3. Most 
trials (n=32) were classified as high quality (≥5), with only four trials classified as low quality 
(<5). High quality trials presented adequate minimal risk of bias during patient selection and 
reported use of random allocation number for the subjects. Details regarding withdrawals were 
reported in 28 trials. Only three of the trials analysed data according to the intention-to-treat 
principle, achieving the highest score of 7.  
Effect of polyphenol intake on HbA1c  
Results of polyphenol supplementation on HbA1c% reduction are presented in the Forest plot in 
figure 2 to 4 (difference in mean and 95% CI) according to health status. The meta-analysis of 
polyphenol intervention on the population as a whole (all three strata) significantly lowered 
HbA1c %: -0.53±0.12, 95% CI: -0.77 to -0.29 units HbA1c% (-5.79 ± 1.3 mmol/mol, 95% CI: -
8.4 to -3.2), compared with the control group (p<0.001, effect size=0.09).  
Looking into individual strata (Figure. 2), polyphenol treatment showed a favourable reduction of 
HbA1c concentrations in the supplemented T2DM subjects compared to control subjects: -
0.21±0.04, 95% CI: -0.29 to -0.121 units HbA1c% (-2.29±0.4 mmol/mol HbA1c, 95% CI -3.2 to 
1.3, p<0.001). In contrary, polyphenols treatment in non-diabetic subjects (Figure 3) did not lead 
to significant (p=0.15) reduction in HbA1c: -0.39± 0.27, 95% CI: -0.92 to 0.15 units HbA1c%; (-
4.3±3.0 mmol/mol HbA1c, 95% CI: -10.1 to 1.6). Similar results were found for the pre-diabetic 
subjects: -0.38±0.31, 95% CI: -0.99 to 0.22 units HbA1c% (-4.2±3.4 mmol/mol HbA1c, 95% CI: 
-10.8 to 2.4, p=0.21). Polyphenol interventions had a larger effect size in T2DM group (effect 
size=0.12) compared to the overall group (effect size=0.09). A significant heterogeneity was 
found for the changes in HbA1c% for non-diabetic and pre-diabetic trials (p<0.001, I
2
 =97.5% 
and 93.2% respectively) and the results are reported with the random-effects model. There was 
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no significant heterogeneity for the T2DM group (p=0.28; I
2
 =10.89), in this case, the results are 
reported based on the fixed-effects model. 
The funnel plots for each group approximated an inverted symmetrical funnel, which suggests 
limited publication bias (Figure. 5). Using Egger regression test, publication bias was found in 
the combined meta-analyses for all strata (b0= -2.80, p=0.003) indicating that the smaller trials 
show a more pronounced effect that the larger ones. This was the case for the T2DM stratum, 
which presented a statistically significant asymmetry (b0= -0.647, p<0.01), but not the non-
diabetic trials (b0=5.37, p=0.08) or the pre-diabetic trials (b0=1.46, p=0.37).  
Sensitivity analysis to explore heterogeneity was performed using the one-study remove 
approach. We found no significant change in HbA1c % reduction between treatment groups in 
each stratum. Similarly, analysis limited to high-quality studies (score ≥5) was performed on the 
T2DM stratum (where no heterogeneity existed) to determine risk of bias due to poorer quality 
studies (eliminated trials are listed in table 3). HbA1c% reduction was still significant when 
analyses were limited to high-quality studies (n=25) and was not changed: -0.27±0.06 units 
HbA1c%, 95% CI: -0.39 to -0.16 (3.0±0.7 mmol/mol HbA1c, 95% CI: -4.3 to -1.7, p<0.001). 
This was not performed for the pre-diabetic and non-diabetic strata since few trials (n=8) with a 
high quality level (except for Banini, 2006) were found. 
Additionally, when analysis was restricted to longer trials (≥ 6 and ≥ 12 weeks) on all three 
stratums combined, reduction in HbA1c became more marked. Including trials lasting 6 weeks or 
longer led to a reduction of -0.40±0.09 units HbA1c%; 95% CI: -0.57 to -0.22% (-4.4±1.0 
mmol/mol, 95% CI: -0.57 to -2.4, p<0.001). Trials lasting 12 weeks or longer led to a reduction 
of -0.38±0.10 units HbA1c%; 95% CI: -0.59, to -0.18 (-4.2±1.1 mmol/mol, 95% CI: -6.4 to -2.0, 
p<0.001). The same was for T2DM stratum lasting 12 weeks or longer with a reduction of -
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0.27±0.07 units HbA1c%, 95% CI: -0.40 to -0.14 (3.0±0.8 mmol/mol; 95% CI: -4.4 to -1.5, 
p<0.001). 
 
Discussion 
Glycated tissue components are recognised as markers of vascular complications, in diabetic as 
well as non-diabetic subjects (Selvin et al., 2010b). As a widely-used example, HbA1c during the 
first 3 months after T2DM diagnosis is a strong determinant of cardiovascular death within 5 
years and can predict microvascular and macrovascular diseases (Kerr et al., 2011; Mulnier et al., 
2006). Fructosamine concentrations have also been associated with cardiovascular mortality 
(Browner et al., 1999; Mittman et al., 2010). Thereby, lowering glycated concentrations after 
diagnosis may reduce long-term risks of diabetes complication.  
Our meta-analysis showed a significant -0.53±0.12 unit reduction in HbA1c% in the total 
population (n=1954) irrespective of diabetes status (equivalent to -5.8±1.3 mmol/mol), which 
was sustained among T2DM individuals (n=1426) but not significant among pre-diabetic and 
non-diabetic subjects, whose baseline HbA1c was lower.  
The ARIC study showed that for every one unit increase in HbA1c% being associated with a 
55% risk of stroke (Selvin et al., 2010a). Overall the EPIC, ARIC and AusDiab studies suggested 
a 18-26% increase in all-cause mortality for each one increase in HbA1c% (Barr et al., 2009; 
Khaw et al., 2004; Selvin et al., 2010a). Assuming a linear association between HbA1c increase 
and risk of comorbidities, a reduction of 0.53 units in HbA1c%, as seen in all subjects combined, 
could result in 14-23% reduction in all-cause mortality and 26% decrease in the risk of stroke. 
Despite the relatively small effect size of the treatment (0.09 for all strata), there is the potential 
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for sizeable clinical and public health significance. As most of polyphenol studies are short 
intervention trials, consequently, long term clinical outcome have not been measure yet. 
Our results are in concordance with a previous meta-analysis assessing cinnamon intake on 
HbA1c (Davis et al., 2011). The six cinnamon trials included by Davis et al. (n= 435 subjects) led 
to a significant decrease in mean HbA1c (0.09%; 95% CI: 0.04 to 0.14). Another meta-analysis 
(6 trials, <3 months, n= 348 subjects) (Zheng et al., 2013) quantifying the effect of green tea 
catechins on glycaemic control failed to observe a significant decrease on HbA1c (-0.04%; 95% 
CI: -0.15 to 0.08%). The green tea trials were based on short durations (<3 months in half of the 
trials), similar to several trials included here in the non-diabetic and pre-diabetic strata, and eight 
trials in the T2DM stratum. Removal of these eight trials in the T2DM stratum did not change the 
outcome of the meta-analysis, with a reduction of HbA1c highly significant (-0.27%; SE: 0.07%; 
95% CI: -0.40 to -0.14; p<0.001). Since HbA1c% is a long-term predictor of diabetes 
complications, any effect should be measured using a marker that reflects a change due to the 
exposure.  
Only 5 trials were found that met the inclusion criteria for non-diabetic and pre-diabetic. Two 
trials included T2DM subjects and these studies were divided for the analysis. Although there 
were more trials that declared HbA1c % in their analysis, the reduction after treatment or baseline 
was not mentioned. This reduced the number of trials included in the meta-analysis. Long-term, 
high quality, randomized control trials are needed to verify the effects of polyphenols 
intervention on HbA1c in non-diabetic and pre-diabetic. Moreover, few of the trials included 
assessed HbA1c concentrations as their primary outcome, so sample sizes were not estimated for 
this outcome. An increased risk of coronary heart disease, ischemic stroke, and death has been 
observed even in the normal concentrations of HbA1c (Selvin et al., 2004). The risks of 
microvascular events can progressively lower down for pre-diabetic individuals when HbA1c 
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concentrations yield 6.5% (Zoungas et al., 2012). Therefore, even a reduction of HbA1c within 
the normal values may be useful to reduce the risk of diabetes, vascular diseases and death.  
The trials included in this meta-analysis had a variety of polyphenol sources, dosage, 
presentation, duration of the RCTs, differences in ethnicity, health condition, heterogeneous 
groups of subjects, and, for T2DM, glucose control level medication, that could have led to a bias 
among the trials, and therefore to the heterogeneity observed. For instance, in the T2DM trials, 
polyphenols were presented principally as capsules or extracts, while in the non-diabetic and pre-
diabetic trials, the main source of polyphenol was food.  
Not all polyphenols have the same properties, and relatively few have been fully assessed for 
their bioavailability and metabolic fate after ingestion, or for effect of the food matrix and 
background dietary compositions (Crozier et al., 2009). This heterogeneity inherent to nutritional 
interventions probably introduces substantial variance in outcomes and should be taken in 
consideration (even for the T2DM stratum) when interpreting the results and drawing 
conclusions. In fact, polyphenol urinary concentration or other biomarkers of intake should be 
measured to indicate compliance and to demonstrate that an increase of polyphenol has been 
achieve during the intervention. And so forth, relate the change in HbA1c concentration to an 
increase in polyphenols intake. In this case, only 7 (Balzer et al., 2008; Curtis et al., 2012; 
Fenercioglu et al., 2010; Kudolo et al., 2005; Pan et al., 2007; Toolsee et al., 2013; Vinson et al., 
2012) of the trial included in the meta-analysis included polyphenol metabolites analysis or 
antioxidant capacity assay. 
A dose-response effect between polyphenol and HbA1c was not included in the meta-analysis 
given the variability of trials. Dietary approaches included in this meta-analysis supplemented the 
diets with 28 to 1500 mg/day polyphenols. Polyphenol rich extracts had a more marked effect in 
reducing HbA1c among the trials. The isoflavonoids extracts doses (125 mg/d) used in the 
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supplements can be achieved with the ingestion of soy products (Song et al., 1998; Rau De 
Almeida Callou et al., 2010). Similarly, a daily intake of 1-3g of cinnamon (27 mg/d of 
coumarin) can be feasible to reduce HbA1c concentrations (He et al., 2005; Shan et al., 2005). On 
the other hand, resveratrol dose (250 mg/d) could be achieve with extracts since red wine, with 
the highest resveratrol content, presents around 3 mg/100 ml (Lamikanra et al., 1996). In terms of 
physiological relevance, a strict and well-designed dietary intervention should be able to deliver 
similar doses of certain polyphenols as those obtained by supplements. It is however still unclear 
how the food matrix and downstream cascade of physiological events associated with food (and 
meal) structure can impact on the biological activity of food bioactives, including polyphenols. A 
Western diet is able to deliver between 109mg to 313mg of polyphenol per day, 820mg and 1.3g 
for a Mediterranean diet (Sowers et al., 2006; Zamora-Ros et al., 2013; Dilis et al., 2010; 
Tresserra-Rimbau et al., 2013; Touvier et al., 2013).  
In summary, the results of the meta-analysis showed that polyphenol supplementation is 
associated with a significant reduction in HbA1c (%) in the total population. This effect is more 
profound in subjects with T2DM, whereas in pre- and non-diabetic subjects the relatively small 
number of published trials, the low study quality and the small effect size of the interventions did 
not allow for the detection of a significant effect. Despite the small effect size of the polyphenol 
supplementation trials, the meta-analysis shows a good potential of such intervention in terms of 
clinical and public health significance that needs further investigation. Importantly, the doses 
supplemented are achievable through dietary modification and offer a large range of 
opportunities for intervention. More long-term controlled trials of high quality are needed 
especially in populations free (but at risk) of diabetes (e.g. those with overweight, high blood 
pressure, or impaired glucose tolerance).  
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Table 1. Characteristics of the trials carried out with non-diabetic individuals, that were included in the analysis 
       HbA1c ± SD 
       Polyphenol  Control 
Study 
Qual
ity 
scor
e 
Cou
ntry 
Desi
gn 
No. 
subj
ects 
Polyphenol 
intervention 
Durat
ion 
(m) 
Pre Post Pre Post 
Non-diabetic 
Banini, 2006 
(Banini et 
al., 2006) 
3 US RCT 23 
Muscadine grape juice 
(150 mL/d) 
<1 
5.5 ± 
0.28 
5.8 ± 
0.85 
5.5 ± 
1.61 
5.2 ± 
0.77 
Brown, 2009 
(Brown et 
al., 2009) 
6 UK 
RDB
CT 
88 
Tea (800mg EGCG/d) 
capsule 
2 
5.28 ± 
0.43 
5.31 ± 
0.05 
5.12 ± 
0.32 
5.22 ± 
0.05 
Dallas, 2013 
(Dallas et al., 
2013) 
6 
Franc
e 
RDB
CT 
95 
Polyphenol-rich fruit 
extract (900mg/d) 
capsule 
3 
5.64 ± 
0.10 
5.95 ± 
0.08 
5.55 ± 
0.10 
6.79 ± 
0.05 
Ogawa, 2013 
(Ogawa et 
al., 2013) 
6 Japan 
RDB
CT 
34 
1000mg/d of acacia 
polyphenol tablet 
2 
5.4 ± 
0.41 
5.4 ± 
0.41 
5.5 ± 
0.41 
5.6 ± 
0.41 
Vinson, 2012 
(Vinson et 
al., 2012) 
5 US 
RCo
T 
18 
6-8 Purple majesty 
Potatoes 
1 
5.6 ± 
0.40 
5.0 ± 
0.40 
5.6 ± 
0.40 
4.7 ± 
0.40 
HbA1c % is expressed as mean ± standard deviation. B, blind; C, controlled; Co, crossover; D, double; 
EGCG, epigallocatechin gallate; R, randomized; S, single; T, trial. High quality score ≥ 5. 
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Table 2. Characteristics of the trials carried out with pre-diabetic individuals, that were included in the analysis 
       HbA1c ± SD 
       Polyphenol  Control 
Study 
Quality 
score 
Country Design 
No. 
subjects 
Polyphenol intervention 
Duration 
(m) 
Pre Post Pre Post 
Pre-diabetic 
Evans, 2012 
(Evans et al., 2012)  
5 US RDBCT 19 
Diabetinol 1500mg/d (nobiletin 
and tangeretin) capsule 
3 6.52 ± 0.75 6.42 ± 0.63 6.39 ± 0.70 6.45 ± 0.47 
Cho, 2012 (Cho et 
al., 2012) 
5 Korea RDBCT 99 
Sajabalssuk (3000mg/d) and 
Pinitol (Positive control: 
1140mg/d) capsule 2.3 
6.28 ± 0.75 5.63 ± 0.57 6.19 ± 1.61 6.51 ± 1.26 
Pinitol (Positive control: 
1140mg/d) capsule 
5.54 ± 1.03 6.05 ± 1.03 
  
Klein, 2011 (Klein 
et al., 2011a) 
6 Brazil RSBCT 29 
Mate Tea (19800mg/d) 
2 
6.1 ± 0.80 5.7 ± 0.86 
  
Mate Tea (19800mg/d) and Diet 
intervention 
5.7 ± 0.47 5.30 ± 0.41 5.97 ± 0.59 5.88 ± 0.81 
Toolsee, 2013 
(Toolsee et al., 
2013) 
6 
Mauritiu
s 
RBGCT 123 
Green tea infusion (6000mg/d) 
male  
3.5 
6.0 ± 0.18 5.9 ± 0.15 6.0 ± 0.14 5.9 ± 0.20 
Green tea infusion (6000mg/d) 
female 6.1 ± 0.19 5.95 ± 0.16 6.0 ± 0.12 5.9 ± 0.12 
HbA1c % is expressed as mean ± standard deviation. B, blind; C, controlled; Co, crossover; D, double; G, gender; R, randomized; S, single; T, 
trial. High quality score ≥ 5. 
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Table 3. Characteristics of the trial carried out with Type 2 Diabetes Mellitus patients, that were included in the analysis 
        HbA1c ± SD 
        Polyphenol Control 
Study Quali
ty 
score 
Coun
try 
Design No. 
subje
cts 
Medicatio
n 
Polyphenol intervention Durat
ion 
(m) 
Pre Post Pre Post 
Balzer, 2008 (Balzer et 
al., 2008) 
6 US RDB
CT 
41 H High Flavonols (963mg/d) vs Low (75mg/d) dose cocoa 
drink 
1 7.0 ± 
0.9 
6.9 ± 
0.90 
7.5 ± 
1.2 
7.5 ± 
1.2 
Banini, 2006 (Banini et 
al., 2006) 
3 US RCT 29 NS Muscadine grape juice (150mL/d) <1 8.4 ± 
2.21 
8.3 ± 
2.21 
5.5 ± 
1.61 
5.2 ± 
0.77 
 Muscadine grape wine (150mL/d) 7.4 ± 
1.58 
6.8 ± 
2.53 
  
 Dealcoholized-Wine (150mL/d) 7.6 ± 
1.50 
7.5 ± 
1.20 
  
Basu, 2013 (Basu et al., 
2013) 
2 US PCS 17 H Pomegranate Polyphenol extracts (1506mg/d) capsule 1 7.51 
± 
0.75 
7.31 
± 
0.53 
6.45 
± 
0.76 
6.45 
± 
0.85 
Bhatt, 2012 (Bhatt et al., 
2012) 
5 India RCT 57 H(M/Gl) Resveratrol capsule (250mg/d) 3 13.7 
± 2.0 
13.1 
± 1.9 
11.4 
± 
1.90 
11.7 
± 1.7 
Blevins, 2007 (Blevins 
et al., 2007) 
7 US RDB
CT 
57 M/Th/H
GMCR 
Cinnamon capsule (1500mg/d) 3 7.2 ± 
0.30 
7.4 ± 
0.10 
7.1 ± 
0.20 
7.2 ± 
0.2 
Campbell, 
2011(Campbell-Tofte et 
al., 2011) 
7 Den
mark 
RDB
CT 
23 M/Ht/Ch Rauvolfia-Citrus Tea (750mL/d) drink 4 6.5 ± 
1.1 
6.1 ± 
1.20 
6.8 ± 
1.00 
6.7 ± 
1.00 
Curtis, 2012 (Curtis et 
al., 2012) 
6 UK RDB
CT 
93 Statin Flavonoid-enriched Chocolate (27000mg/d: 90mg 
epicatechin + 100mg isoflavones aglycone equivalents) 
12 7.13 
± 
0.96 
7.22 
± 
1.03 
7.25 
± 
1.01 
7.44 
± 
1.15 
Fenercioglu, 2010 
(Fenercioglu et al., 
2010) 
5 Turk
ey 
RDB
CT 
114 M/A Pomegranate extract (500mg), Green tea extract (300mg) 
and vitamin C (60mg) capsule 
3 7.36 
± 
1.78 
7.00 
± 
0.98 
7.71 
± 
2.33 
7.1 ± 
2.13 
Fukino, 2005 (Fukino et 
al., 2005) 
4 Japan RCT 66 - Green tea extract/powder (544mg polyphenol) 2 6.2 ± 
1.9 
6.0 ± 
1.90 
6.1 ± 
1.30 
6.4 ± 
1.40 
Fukino, 2008 (Fukino et 
al., 2008) 
5 Japan RCoN
BNW
T 
60 H Green tea extract/powder (544mg polyphenol + 102 mg 
caffeine) 
4 6.2 ± 
2.0 
5.8 ± 
1.70 
6.1 ± 
1.30 
5.9 ± 
1.40 
Howes, 2003 (Howes et 
al., 2003) 
6 Austr
alia 
RDB
CoT 
19 M/Su/A Isoflavone tablet (50mg/d formononetin, 5mg/d biochanin, 
with genistein and daidzein) 
3 7.16 
± 
0.63 
7.12 
± 
2.97 
7.16 
± 
0.63 
7.11 
± 
2.67 
Hsu, 2011 (Hsu et al., 
2011) 
6 Taiw
an 
RDB
CT 
68 H Decaffeinated green tea extract (1500mg/d; 856 mg/d of 
EGCG and other catechins) capsule 
4 8.4 ± 
2.1 
8.00 
± 
8.4 ± 
1.80 
8.2 ± 
1.9 
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2.00 
Hussain, 2007 (Hussain 
2007) 
5 Iraq RDB
CT 
59 H (Gl) Silymarin (200mg/d + glibenclamide) capsule, Control (10 
mg/d glibenclamide) 
4 8.91 
± 
0.76 
7.45 
± 
0.81 
8.78 
± 
0.50 
8.74 
± 
0.46 
 placebo capsule (+ glibenclamide) 8.76 
± 
0.67 
8.71 
± 
0.63 
  
Jayawardena, 2005 
(Jayawardena et al., 
2005) 
5 Sir 
Lank
a 
RDB
CoT 
51 H (M/Gl) Kothala Himbutu Tea infusion 6 6.8 ± 
0.9 
6.29 
± 
1.02 
6.7 ± 
0.90 
6.65 
± 
1.04 
Klein, 2011 (Klein et 
al., 2011a) 
6 Brazi
l 
RSBC
T 
29 H 
(M/Su) 
Mate Tea (19800mg/d) 2 7.6 ± 
2.99 
6.7 ± 
2.65 
6.5 ± 
0.60 
6.4 ± 
0.60 
 Mate Tea (19800mg/d) and Diet intervention 6.8 ± 
0.90 
6.7 ± 
1.20 
  
Kudolo, 2005 (Kudolo 
et al., 2005) 
4 US RCT 19 H 
(M/Gly) 
Ginkgo biloba extract tablet (120mg/d) in normal and high 
cholesterol T2DM subjects 
3 6.9 ± 
0.90 
7.30 
± 
1.60 
7.30 
± 
1.40 
7.20 
± 
2.00 
Lu, 2012 (Lu et al., 
2012) 
6 Chin
a 
RDB
CT 
66 Gli Low-dose cinnamon tablets(120mg/d) 3 8.9 ± 
1.24 
8.23 
± 
0.99 
8.93 
± 
1.14 
8.93 
± 
1.04 
 high-dose cinnamon tablets (360mg/d) 8.92 
± 
1.35 
8.00 
± 
1.00 
  
MacKenzie, 2007 
(Mackenzie et al., 2007) 
6 US RDB
CT 
49 H 
(M/Gly) 
Tea extract (375mg/d: 150mg green tea catechins + 75mg 
black tea theaflavins + 150mg others tea Polyphenols) 
capsule 
3 7.2 ± 
0.80 
7.5 ± 
0.90 
7.1 ± 
0.80 
7.5 ± 
0.92 
 Tea extract (750mg/d: 300mg green tea catechins and 
150mg black tea theaflavins, 300mg other tea polyphenols) 
capsule 
7.1 ± 
0.9 
7.6 ± 
1.15 
  
Mang, 2006 (Mang et 
al., 2006) 
6 Germ
any 
RDB
CT 
65 M/Su/Th 3 capsule/d of cinnamon extract (112mg aqueous purified 
extract with <0.1% coumarins and <0.1%essential oil) 
capsule 
4 6.86 
± 
1.00 
6.83 
± 
0.83 
6.71 
± 
0.73 
6.68 
± 
0.70 
Mellor, 2010 (Mellor et 
al., 2010) 
5 UK RDB
CoT 
12 M/Statin 3 bars/d of high Polyphenol Chocolate (16.6mg/d 
epicatechins) vs low polyphenol chocolate (<2mg) 
4 6.4 ± 
0.49 
6.5 ± 
0.49 
6.40 
± 
0.20 
6.4 ± 
0.50 
Mirzaei, 2010 (Mirzaei 
et al., 2010) 
5 Iran RDB
CT 
72 - Green tea extract (150mg/d: 150 mg caffeine, 240 mg 
polyphenols) capsule 
2 7.21 
± 
1.63 
7.25 
± 
1.87 
7.61 
± 
2.04 
8.17 
± 
2.09 
Movahed, 2013 
(Movahed et al., 2013) 
6 Iran RGD
BCT 
64 H 
(M/Gl/St
atin) 
Resveratrol capsule (100mg/d) 1.5 8.6 ± 
1.39 
7.60 
± 
1.32 
8.30 
± 
2.37 
8.50 
± 
2.46 
Nagao, 2009 (Nagao et 
al., 2009) 
6 Japan RDB
CoT 
43 Su/Th Catechin green tea (catechin: 582.8mg/d) vs green tea 
(catechin: 96.3mg/d) drink 
3 6.68 
± 
0.77 
6.31 
± 
0.77 
6.59 
± 
0.90 
6.58 
± 
1.03 
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Pan, 2007 (Pan et al., 
2007) 
6 Chin
a 
RDB
CT 
68 H/Ht Lignan capsule(360mg/d) 3 7.71 
± 
1.42 
7.06 
± 
1.15 
7.01 
± 
1.29 
7.11 
± 
1.29 
Ryan, 2000(Ryan et al., 
2000) 
6 Cana
da 
RSBC
T 
40 H Herbal tea(Populus tremulides and Heracleum 
lanatum,250mL/d) vs Placebo Chinese green tea, mint and 
fennel seed (250mL/d) 
< 1 7.5 ± 
1.80 
7.9 ± 
1.60 
8.1 ± 
1.50 
8.30 
± 
1.30 
Tome-Carneiro, 2013 
(Tome-Carneiro et al., 
2013) 
6 Spain RTrB
CT 
35 Ht/Statin
/BB/RAS
B 
Green tea extract (350mg/d: 151mg phenolics) capsule 12 7.1 ± 
1.30 
7.2 ± 
1.2 
7.0 ± 
1.0 
7.40 
± 
1.00 
 Green tea extract (139mg phenolics) + Resveratrol (8.1mg) 
capsule 
7.4 ± 
1.60 
7.60 
± 
1.50 
  
Vafa, 2012 (Vafa et al., 
2012) 
5 Iran RDB
CT 
37 M/Gli Cinnamon (3000mg/d) capsule 2 7.35 
± 
0.51 
6.90 
± 
0.77 
7.28 
± 
0.56 
7.18 
± 
0.74 
Vanschoonbeek, 2006 
(Vanschoonbeek et al., 
2006) 
5 Neth
erlan
ds 
RDB
CT 
25 M/Su/Th Cinnamon (1500mg/d) capsule 1.5 7.4 ± 
1.04 
7.5 ± 
1.04 
7.1 ± 
0.72 
7.20 
± 
0.72 
Zibadi, 2008(Zibadi et 
al., 2008) 
7 US RDB
CT 
48 ACE Pynogenol (125mg/d) capsule 3 7.9 ± 
1.47 
7.10 
± 
0.98 
8.1 ± 
0.40 
8.00 
± 
1.96 
HbA1c % is expressed as mean ± standard deviation. A, ascarbose; ACE, angiotensin-converting enzyme; B, blind; BB, β-blockers; 
D, double; C, controlled; Co, crossover; G, gender; Gl, glibenclamide; Gli, gliclazide; Gly, glyburide; H, hypoglycemic agent; 
HGMCR, hydroxymethylglutaryl-CoA reductase; Ht, hypertensive agent; M, metformin; N, no; PCS, pilot clinical study; R, 
randomized; S, single; Su, sulphonylureas: T, trial; Th, thiazoledinediones, Tr, triple; W, washout. High quality score ≥ 5. 
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Table 4. HbA1c concentrations (Mean ± SD) of the subjects included in the analysis 
Subjects 
Baseline Endpoint 
% mmol/mol % mmol/mol 
Non-diabetic (n= 258) 5.47 ± 0.40 36.28 ± 4.37 5.76 ± 0.35 39.45 ± 1.31 
Pre-diabetic (n= 270) 6.06 ± 0.68 42.73 ± 7.43 5.79 ± 0.63 39.78 ± 4.17 
T2DM (n=1426) 7.44 ± 1.19 57.81 ± 8.88 7.33 ± 1.22 56.61 ± 9.26 
Treated (n= 1053) 7.59 ± 1.26 59.45 ± 9.51 7.36 ± 1.28 56.94 ± 9.85 
Control (n= 901) 6.92 ± 0.99 52.13 ± 7.15 6.94 ± 1.00 52.35 ± 7.24 
Total (n= 1954) 7.03 ± 1.03 50.22 ± 10.60 6.94 ± 1.04 49.30 ± 10.70 
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Figure 1. Flow diagram of the study selection process 
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